Skip to main content
Premium Trial:

Request an Annual Quote

Epoch Biosciences Said Increased Sales of MGB Eclipse Helped Buoy Sales in Q3

NEW YORK, Oct. 26 (GenomeWeb News) - Epoch Biosciences today reported increased losses amidst rising revenues for the third quarter, mainly due to a non-cash charge.


Total revenues for the quarter ended Sept. 30 increased to $2.4 million from $2 million during the same period last year. This is due both to an increase in product sales, led by the MGB Eclipse products, and an increase in license fees and royalties.


Epoch's R&D costs decreased to $918,000 from $952,000 during the same quarter a year ago.


The company's net loss for the quarter increased to $1.2 million, or $.04 per share, from $332,000, or $.01 per share, during the same period last year. This increase resulted from a $823,000 non-cash charge resulting from the termination of a technology license from Incyte, and changes in the fair value of common stock warrants of $34,000, according to the company. Excluding these, net loss would have been $426,000, or $.01 per share.


As of Sept. 30, Epoch held $8.5 million in cash and cash equivalents, and $102,000 in restricted cash.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.